News
TCRX
1.060
-0.93%
-0.010
Weekly Report: what happened at TCRX last week (0622-0626)?
Weekly Report · 3d ago
TScan Therapeutics to join H.C. Wainwright Cell Therapy Virtual Conference fireside chat
PUBT · 06/24 11:01
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), TScan Therapeutics (TCRX) and PACS Group Inc (PACS)
TipRanks · 06/23 12:30
TScan Therapeutics Price Target Maintained With a $5.00/Share by Wedbush
Dow Jones · 06/23 12:30
Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price Target
Benzinga · 06/23 12:20
TScan Therapeutics Price Target Maintained With a $6.00/Share by Needham
Dow Jones · 06/23 11:52
Needham Reiterates Buy on TScan Therapeutics, Maintains $6 Price Target
Benzinga · 06/23 11:43
Analysts Conflicted on These Healthcare Names: TScan Therapeutics (TCRX), Exelixis (EXEL) and AbbVie (ABBV)
TipRanks · 06/23 11:20
TScan Therapeutics: Early ALLOHA Phase 1 Efficacy and Safety Reinforce Late-Stage Plans; Buy Rating and $6 Price Target Maintained
TipRanks · 06/23 10:26
Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Relmada Therapeutics (RLMD)
TipRanks · 06/23 10:20
TScan Therapeutics: ALLOHA Data, Streamlined Manufacturing Bolster Buy Rating with $7 Price Target Maintained
TipRanks · 06/23 10:16
TScan publishes ALLOHA Cohort C Phase 1 presentation for TSC-101 TCR-T therapy in post-transplant AML, ALL and MDS
PUBT · 06/22 14:33
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial
TipRanks · 06/22 11:30
TScan Therapeutics presents data from Cohort C of ALLOHA trial
TipRanks · 06/22 11:30
TScan Says Cancer Therapy Data Support Move to Phase 3 Trial
Benzinga · 06/22 11:08
TScan reports Phase 1 Cohort C data showing 11 of 14 patients reach complete donor chimerism after TSC-101 infusion
PUBT · 06/22 11:01
TSCAN THERAPEUTICS - ON TRACK TO ENROLL FIRST PATIENT IN PHASE 3 ALLOHA-2 STUDY OF TSC-101 THIS MONTH
Reuters · 06/22 11:00
Weekly Report: what happened at TCRX last week (0615-0619)?
Weekly Report · 06/22 09:38
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
Barchart · 06/22 06:00
More
Webull provides a variety of real-time TCRX stock news. You can receive the latest news about Tscan Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TCRX
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.